Blueprint Medicine Gains US Approval For First Drug, Precision Medicine Ayvakit

Targets Mutation In GIST tumors

The FDA has granted full approval to the drug based on Phase I efficacy data and safety studies, reflecting lack of existing treatment options

Blueprint_Medicines_Logo

Blueprint Medicines Corp. has gained its first ever drug approval, the US Food and Drug Administration giving the green light to Ayvakit (avapritinib).

The US regulator is continuing in 2020 as it ended 2019, turning around approvals on new drugs far ahead of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip